Behçet's disease

Orphanet Journal of Rare Diseases

Volumn 7, Issue 1, 2012, Pages

  Saadoun, David ^a   Wechsler, Bertrand ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Autoimmunity; Beh et's disease; Uveitis; Vasculitis

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PENTOXIFYLLINE; SUCRALFATE; THALIDOMIDE;

ANTIPHOSPHOLIPID SYNDROME; AORTA ARCH SYNDROME; ARTHRITIS; BEHCET DISEASE; CLINICAL FEATURE; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; ENVIRONMENTAL FACTOR; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; GENITAL ULCER; GEOGRAPHIC DISTRIBUTION; HEMATOLOGIC DISEASE; HUMAN; IMMUNE DEFICIENCY; KIDNEY DISEASE; LUNG DISEASE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PATHOGENESIS; POLYCHONDRITIS; PROGNOSIS; REVIEW; SARCOIDOSIS; UVEITIS; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AUTOIMMUNITY; BEHCET SYNDROME; HUMANS; IMMUNOMODULATION; RARE DISEASES; STEROIDS; YOUNG ADULT;

EID: 84859645480     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-7-20     Document Type: Review

References (37)

1. A historical review of early descriptions of Adamantiades-Behcet's disease. Zouboulis CC, Keitel W, J Invest Dermatol 2002 119 1 201 205 10.1046/j.1523-1747.2002.01798.x 12164950
2. A proposed classification of the immunological diseases. McGonagle D, McDermott MF, PLoS Med 2006 3 8 297 10.1371/journal.pmed.0030297 16942393
3. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease, Lancet 1990 335 8697 1078 1080 1970380
4. Close association of HLA-Bw51 with Behcet's disease. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M, Arch Ophthalmol 1982 100 9 1455 1458 10.1001/archopht.1982.01030040433013 6956266
5. HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behcet's disease. Verity DH, Wallace GR, Vaughan RW, Kondeatis E, Madanat W, Zureikat H, Fayyad F, Marr JE, Kanawati CA, Stanford MR, Tissue Antigens 1999 54 3 264 272 10.1034/j.1399-0039.1999.540307.x 10519363
6. Familial aggregation of Behcet's disease in Turkey. Gul A, Inanc M, Ocal L, Aral O, Konice M, Ann Rheum Dis 2000 59 8 622 625 10.1136/ard.59.8.622 10913059
7. Mortality in Behcet's disease. Saadoun D, Wechsler B, Desseaux K, Le Thi Huong D, Amoura Z, Resche-Rigon M, Cacoub P, Arthritis Rheum 2010 62 9 2806 2812 10.1002/art.27568 20496419
8. Renal Behcet's disease: a cumulative analysis. Akpolat T, Akkoyunlu M, Akpolat I, Dilek M, Odabas AR, Ozen S, Semin Arthritis Rheum 2002 31 5 317 337 10.1053/sarh.2002.31721 11965596
9. Ocular manifestations of Behcet's disease. Saadoun D, Cassoux N, Wechsler B, Boutin D, Terrada C, Lehoang P, Bodaghi B, Cacoub P, Rev Med Interne 2010 31 8 545 550 10.1016/j.revmed.2009.04.014 20413190
10. Azathioprine in severe uveitis of Behcet's disease. Saadoun D, Wechsler B, Terrada C, Hajage D, Le Thi Huong D, Resche-Rigon M, Cassoux N, Le Hoang P, Amoura Z, Bodaghi B, Cacoub P, Arthritis Care Res (Hoboken). 2010 62 12 1733 1738 10.1002/acr.20308
11. Major vessel involvement in Behcet's disease: an update. Calamia KT, Schirmer M, Melikoglu M, Curr Opin Rheumatol 2011 23 1 24 31 10.1097/BOR.0b013e3283410088 21124084
12. Long-Term Outcome of Arterial Lesions in Behcet Disease: A Series of 101 Patients. Saadoun D, Asli B, Wechsler B, Houman H, Geri G, Desseaux K, Piette JC, Huong DL, Amoura Z, Salem TB, Cluzel P, Koskas F, Resche-Rigon M, Cacoub P, Medicine (Baltimore). 2012 91 1 18 24 10.1097/MD.0b013e3182428126
13. Pathologic features of Behcet's syndrome: a review of Japanese autopsy registry data. Lakhanpal S, Tani K, Lie JT, Katoh K, Ishigatsubo Y, Ohokubo T, Hum Pathol 1985 16 8 790 795 10.1016/S0046-8177(85)80250-1 4018777
14. Pulmonary artery aneurysms in Behcet syndrome. Hamuryudan V, Er T, Seyahi E, Akman C, Tuzun H, Fresko I, Yurdakul S, Numan F, Yazici H, Am J Med 2004 117 11 867 870 10.1016/j.amjmed.2004.05.027 15589493
15. Cardiovascular manifestations of Behcet's disease. Wechsler B, Du LT, Kieffer E, Ann Med Interne (Paris). 1999 150 7 542 554
16. Spectrum of cardiac lesions in behcet disease: a series of 52 patients and review of the literature. Geri G, Wechsler B, Thi Huong Du L, Isnard R, Piette JC, Amoura Z, Resche-Rigon M, Cacoub P, Saadoun D, Medicine (Baltimore). 2012 91 1 25 34 10.1097/MD.0b013e3182428f49
17. Behcet disease and corticotherapy. Wechsler B, Piette JC, Godeau P, Presse Med 1999 28 33 1819 10584113
18. Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients, The Neuro-Behcet Study Group. Akman-Demir G, Serdaroglu P, Tasci B, Brain 1999 122 Pt 11 2171 2182 10545401
19. Neurological manifestations of Behcet's disease. Wechsler B, Sbai A, Du-Boutin LT, Duhaut P, Dormont D, Piette JC, Rev Neurol (Paris). 2002 158 10 Pt 1 926 933 12407301
20. Cerebral venous thrombosis in Behcet's disease. Saadoun D, Wechsler B, Resche-Rigon M, Trad S, Le Thi Huong D, Sbai A, Dormont D, Amoura Z, Cacoub P, Piette JC, Arthritis Rheum 2009 61 4 518 526 10.1002/art.24393 19333987
21. Gastrointestinal involvement in Behcet's syndrome: a controlled study. Yurdakul S, Tuzuner N, Yurdakul I, Hamuryudan V, Yazici H, Ann Rheum Dis 1996 55 3 208 210 10.1136/ard.55.3.208 8712889
22. New insights into the pathogenesis of Behcet's disease. de Chambrun MP, Wechsler B, Geri G, Cacoub P, Saadoun D, Autoimmun Rev 2011 Epub ahead of print
23. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behcet's disease. Lehner T, Int Rev Immunol 1997 14 1 21 32 10.3109/08830189709116842 9203024
24. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, Le JM, Yang B, Korman BD, Cakiris A, Aglar O, Emrence Z, Azakli H, Ustek D, Tugal-Tutkun I, Akman-Demir G, Chen W, Amos CI, Dizon MB, Kose AA, Azizlerli G, Erer B, Brand OJ, Kaklamani VG, Kaklamanis P, Ben-Chetrit E, Stanford M, Fortune F, Ghabra M, Ollier WE, Cho YH, Bang D, O'Shea J, Wallace GR, Gadina M, Kastner DL, Gul A, Nat Genet 2010 42 8 698 702 10.1038/ng.625 20622878
25. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, Ito N, Kera J, Okada E, Yatsu K, Song YW, Lee EB, Kitaichi N, Namba K, Horie Y, Takeno M, Sugita S, Mochizuki M, Bahram S, Ishigatsubo Y, Inoko H, Nat Genet 2010 42 8 703 706 10.1038/ng.624 20622879
26. Histopathology of central nervous system lesions in Behcet's disease. Hirohata S, J Neurol Sci 2008 267 1-2 41 47 17976652
27. Role of gamma delta T cells in pathogenesis and diagnosis of Behcet's disease. Hasan A, Fortune F, Wilson A, Warr K, Shinnick T, Mizushima Y, van der Zee R, Stanford MR, Sanderson J, Lehner T, Lancet 1996 347 9004 789 794 10.1016/S0140-6736(96)90868-5 8622334
28. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease. Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D, Tran TA, Bodaghi B, Musset L, Soumelis V, Klatzmann D, Cacoub P, Saadoun D, J Allergy Clin Immunol 2011 128 3 655 664 10.1016/j.jaci.2011.05.029 21724243
29. EULAR recommendations for the management of Behcet disease. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger N, Yurdakul S, Yazici H, Ann Rheum Dis 2008 67 12 1656 1662 10.1136/ard.2007.080432 18245110
30. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, Yurdakul S, Yazici H, Medicine (Baltimore). 2003 82 1 60 76 10.1097/00005792-200301000-00006
31. A controlled trial of azathioprine in Behcet's syndrome. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt GE, et al. N Engl J Med 1990 322 5 281 285 10.1056/NEJM199002013220501 2404204
32. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Arida A, Fragiadaki K, Giavri E, Sfikakis PP, Semin Arthritis Rheum 2011 41 1 61 70 10.1016/j.semarthrit.2010.09.002 21168186
33. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet's disease. Deuter CM, Zierhut M, Mohle A, Vonthein R, Stobiger N, Kotter I, Arthritis Rheum 2010 62 9 2796 2805 10.1002/art.27581 20518075
34. Colchicine versus placebo in Behcet's disease: randomized, double-blind, controlled crossover trial. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, Shahram F, Nadji A, Shams H, Chams-Davatchi C, Mod Rheumatol 2009 19 5 542 549 10.1007/s10165-009-0200-2 19597921
35. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H, Ann Intern Med 1998 128 6 443 450 9499327
36. Successful treatment of Behcet disease with pentoxifylline. Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A, Ann Intern Med 1996 124 10 891 893 8610918
37. Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study. Sharquie KE, Najim RA, Abu-Raghif AR, J Dermatol 2002 29 5 267 279 12081158